The Indian POMC Genetic Obesity Drugs market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Proopiomelanocortin (POMC) is the polypeptide precursor of several biologically active melanocortin peptides that have important roles in the regulation of food intake and energy homeostasis, adrenal steroidogenesis, melanocyte stimulation, and immune modulation. The prevalence of overweight and obesity in India is increasing faster than the world average. For instance, the prevalence of overweight increased from 8.4% to 15.5% among women between 1998 and 2019, and the prevalence of obesity increased from 2.2% to 5.1% over the same period. The high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.
Increasing prevalence of POMC Genetic obesity is propelling the demand for these drugs in India. The growing incidence of lifestyle diseases. Obesity-linked disorders such as heart attacks, strokes, diabetes and cancer are being increasingly reported, particularly in the rapidly flourishing urban centres in India. The growing awareness among the patient about the weight gains and associated impacts on other health disorders is attracting the patients towards this medication. The increasing adoption of a sedentary lifestyle and unhealthy diet plans along with the lack of exercise has led to increased body weight and adoption of POMC Genetic Obesity drugs. The lack of weight management among the people and false mind-sets of the people are the two factors restraining the growth of these market.